An overview of class III electrophysiological agents: a new generation of antiarrhythmic therapy.

Publisher Summary This chapter gives an overview of class III electrophysiological agents, which are considered a new generation of antiarrhythmic therapy. Arrhythmias can range from isolated PVC's, coupled beats, non-sustained ventricular tachyarrhythmias (NSVT), sustained ventricular tachyarrhythmias (SVT) and, ultimately, ventricular fibrillation (VF). It is generally agreed that the most serious arrhythmias, SVT and VF, arise by re-entrant mechanisms. That is, a propagated impulse follows a pathway, which returns to its origin and re-excites the original tissue, thus forming a continuous loop for the aberrant impulse. The re-entrant pathway is dependent on conduction velocity, path length and the refractory period of the tissue. If these parameters remain constant, then an ordered re-entrant mechanism results (for example, NSVT, SVT); if multiple pathways exist and continuously change with time, then random re-entry results (VF). Sufficient change in any one of the parameters breaks the loop and terminates the arrhythmia. Similarly, these parameters (for example, conduction velocity or refractoriness) can be altered in a beneficial manner to prevent a specific re-entrant route from forming.

[1]  W. Gould,et al.  Sulfonanilides. I. Monoalkyl- and arylsulfonamidophenethanolamines. , 1966, Journal of medicinal chemistry.

[2]  T. Narahashi,et al.  3,4-diaminopyridine. A potent new potassium channel blocker. , 1978, Biophysical journal.

[3]  J. K. Smallwood,et al.  Clofilium and Other Class III Agents , 1989 .

[4]  J. Papp,et al.  The effect of altered thyroid state on atrial intracellular potentials , 1970, The Journal of physiology.

[5]  M. Davies,et al.  Attenuation of Class 3 and Sinus Node Effects of Amiodarone by Experimental Hypothyroidism , 1989, Journal of cardiovascular pharmacology.

[6]  H. Brasch Influence of the optical isomers (+)‐ and (−)−naloxone on beating frequency, contractile force and action potentials of guinea‐pig isolated cardiac preparations , 1986, British journal of pharmacology.

[7]  T. N. James,et al.  Acute effects of amiodarone upon the canine sinus node and atrioventricular junctional region. , 1983, The Journal of clinical investigation.

[8]  H. Refsum,et al.  Prolonged action potential duration of guinea-pig heart muscle after pethidine. , 1990, Pharmacology & toxicology.

[9]  I. Kodama,et al.  Effects of OPC‐88117, a new antiarrhythmic agent, on the electrophysiological properties of rabbit isolated hearts , 1989, British journal of pharmacology.

[10]  A. Raine,et al.  Adaptation to prolonged beta-blockade of rabbit atrial, purkinje, and ventricular potentials, and of papillary muscle contraction. Time-course of development of and recovery from adaptation. , 1981, Circulation research.

[11]  A. Brown,et al.  5-Hydroxytryptamine antagonist ICS 205-930 blocks cardiac potassium, sodium and calcium currents. , 1988, The Journal of pharmacology and experimental therapeutics.

[12]  J. Hershman,et al.  Effects of Desethylamiodarone on Thyroid Hormone Metabolism in Rats: Comparison with the Effects of Amiodarone , 1986, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[13]  B. Lucchesi,et al.  Antiarrhythmic and antifibrillatory actions of the levo- and dextrorotatory isomers of sotalol. , 1984, Journal of cardiovascular pharmacology.

[14]  M. B. Rosenbaum,et al.  Control of tachyarrhythmias associated with Wolff-Parkinson-White syndrome by amiodarone hydrochloride. , 1974, The American journal of cardiology.

[15]  A. Damato,et al.  Electrophysiologic effects of bretylium tosylate on single fibers of the canine specialized conducting system and ventricle. , 1970, The Journal of pharmacology and experimental therapeutics.

[16]  Y. Q. Xu,et al.  Study of the effects and mechanisms of berberine on slow-response action potentials. , 1990, Journal of electrocardiology.

[17]  J. Bigger,et al.  Efficacy, safety, and tolerance of d-sotalol in patients with refractory supraventricular tachyarrhythmias. , 1989, American heart journal.

[18]  G. Duker,et al.  — A new, potent class III antiarrhythmic agent , 1990 .

[19]  J. L. Kenyon,et al.  4-Aminopyridine and the early outward current of sheep cardiac Purkinje fibers , 1979, The Journal of general physiology.

[20]  D. Wyse,et al.  Melperone: Electrophysiologic and Antiarrhythmic Activity in Humans , 1990, Journal of cardiovascular pharmacology.

[21]  H. Duff,et al.  Amiloride. Antiarrhythmic and electrophysiological activity in the dog. , 1988, Circulation.

[22]  A. Kling,et al.  Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. , 1986, The New England journal of medicine.

[23]  D. Wyse,et al.  Electropharmacology of amiodarone therapy initiation. Time courses of onset of electrophysiologic and antiarrhythmic effects. , 1989, Circulation.

[24]  M. Morad,et al.  Tedisamil blocks the transient and delayed rectifier K+ currents in mammalian cardiac and glial cells. , 1990, The Journal of pharmacology and experimental therapeutics.

[25]  B Lown,et al.  The Coronary Care Unit: New Perspectives and Directions , 1967 .

[26]  G. Feld,et al.  Effects of N-acetylprocainamide and recainam in the pharmacologic conversion and suppression of experimental canine atrial flutter: significance of changes in refractoriness and conduction. , 1988, Journal of cardiovascular pharmacology.

[27]  E. Williams,et al.  Effects on cardiac muscle of the β‐adrenoceptor blocking drugs INPEA and LB46 in relation to their local anaesthetic action on nerve , 1971, British journal of pharmacology.

[29]  M. Kienzle,et al.  Enhanced efficacy of oral sotalol for sustained ventricular tachycardia refractory to type I antiarrhythmic drugs. , 1988, The American journal of cardiology.

[30]  M. Bacaner Quantitative comparison of bretylium with other antifibrillatory drugs , 1968 .

[31]  R. DeVita,et al.  Rational design of 4-[(methylsulfonyl)amino]benzamides as class III antiarrhythmic agents. , 1987, Journal of medicinal chemistry.

[32]  L. Cobb,et al.  Prolongation of cardiac refractory times in man by clofilium phosphate, a new antiarrhythmic agent. , 1983, American heart journal.

[33]  D. Davey,et al.  Synthesis of novel (aryloxy)propanolamines and related compounds possessing both class II and class III antiarrhythmic activity. , 1990, Journal of medicinal chemistry.

[34]  E. Platia,et al.  Dose‐ranging studies of clofilium, an antiarrhythmic quaternary ammonium , 1984, Clinical pharmacology and therapeutics.

[35]  R. Deana,et al.  Properties of a new calcium ion antagonist on cellular uptake and mitochondrial efflux of calcium ions. , 1984, The Biochemical journal.

[36]  J. Hill,et al.  Electrophysiologic effects of amiloride in canine Purkinje fibers: evidence for a delayed effect on repolarization. , 1985, The Journal of pharmacology and experimental therapeutics.

[37]  J. Mason Drug therapy: amiodarone , 1987 .

[38]  P. Kowey,et al.  The effect of bretylium and clofilium on dispersion of refractoriness and vulnerability to ventricular fibrillation in the ischemic feline heart. , 1985, American heart journal.

[39]  B. G. Benfey Function of myocardial α-adrenoceptors , 1987 .

[40]  H. Duff,et al.  Amiodarone: biochemical evidence for binding to a receptor for class I drugs associated with the rat cardiac sodium channel. , 1989, Circulation research.

[41]  M. Rosen,et al.  Electrophysiologic effects of ketanserin on canine Purkinje fibers, ventricular myocardium and the intact heart. , 1989, The Journal of pharmacology and experimental therapeutics.

[42]  W. Kannel,et al.  Sudden unexpected death during ambulatory electrocardiographic monitoring. The Framingham Study. , 1983, The American journal of medicine.

[43]  H. Hayashi,et al.  Effects of pantethine on action potential of canine papillary muscle during hypoxic perfusion. , 1985, Japanese heart journal.

[44]  D. Echt,et al.  Evaluation of antiarrhythmic drugs on defibrillation energy requirements in dogs. Sodium channel block and action potential prolongation. , 1989, Circulation.

[45]  J. Bigger,et al.  NEW DRUGS. , 1979, Canadian Medical Association journal.

[46]  S. Olsson,et al.  Effects of acute and chronic beta-receptor blockade on ventricular repolarisation in man. , 1981, British heart journal.

[47]  A. Gillis,et al.  Clinical Pharmacokinetics of the Newer Antiarrhythmic Agents , 1984, Clinical pharmacokinetics.

[48]  S. Nattel,et al.  Concentration dependence of class III and beta-adrenergic blocking effects of sotalol in anesthetized dogs. , 1989, Journal of the American College of Cardiology.

[49]  T. Ozawa,et al.  Effects of antiarrhythmic agents classified as class III group on ischaemia‐induced myocardial damage in canine hearts , 1990, British journal of pharmacology.

[50]  M. Fujiwara,et al.  Relationship between the effects of Goniopora toxin on action potential and on contractile force in guinea-pig papillary muscle. , 1981, Japanese journal of pharmacology.

[51]  P. Touboul,et al.  Effects of intravenous sotalol in patients with atrioventricular accessory pathways. , 1987, American heart journal.

[52]  H. Oinuma,et al.  4'-[(4-Piperidyl)carbonyl]methanesulfonanilides as potent, selective, bioavailable class III antiarrhythmic agents. , 1990, Journal of medicinal chemistry.

[53]  B. Singh,et al.  A third class of anti‐arrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474 , 1970, British journal of pharmacology.

[54]  A. Varró,et al.  Rate-dependent electrophysiological effects of OPC-8212: comparison to sotalol. , 1989, European journal of pharmacology.

[55]  E. Williams Is Phosphodiesterase Inhibition Arrhythmogenic? Electrophysiologic Effects in Pithed Rats and in Normoxic and Hypoxic Rabbit Atria of Enoximone, a New Cardiotonic Agent , 1987 .

[56]  A. Mugelli,et al.  Antiarrhythmic properties of naloxone: an electrophysiological study on sheep cardiac Purkinje fibers. , 1989, European journal of pharmacology.

[57]  H. Selnick,et al.  Suppression of Lethal Ischemic Ventricular Arrhythmias by the Class III Agent E4031 in a Canine Model of Previous Myocardial Infarction , 1990, Journal of cardiovascular pharmacology.

[58]  C. Kawai,et al.  Electrophysiological effects of melperone on isolated rabbit heart muscles , 1988, British journal of pharmacology.

[59]  M Gwilt,et al.  Selective class III antiarrhythmic agents. 1 Bis(arylalkyl)amines. , 1990, Journal of medicinal chemistry.

[60]  H. Refsum,et al.  Class III antiarrhythmic action linked with positive inotropy: effects of the d- and l-isomer of sotalol on isolated rat atria at threshold and suprathreshold stimulation. , 1988, Pharmacology & toxicology.

[61]  L. Opie,et al.  KC 8857, a new compound with combined bradycardic and positive inotropic effects , 1987 .

[62]  A. Waldo,et al.  Effects of N-acetylprocainamide on experimental atrial flutter and atrial electrophysiologic properties in conscious dogs with sterile pericarditis: comparison with the effects of quinidine. , 1987, Journal of the American College of Cardiology.

[63]  S. Wong,et al.  Synthesis and antiarrhythmic activity of novel 3-alkyl-1-[omega-[4-[(alkylsulfonyl)amino]phenyl]-omega- hydroxyalkyl]-1H-imidazolium salts and related compounds. , 1987, Journal of medicinal chemistry.

[64]  P. Taggart,et al.  Class III action of β-blocking agents , 1984 .

[65]  Z. Szilvássy,et al.  7-oxo-PgI2 induced late appearing and long-lasting electrophysiological changes in the heart in situ of the rabbit, guinea-pig, dog and cat. , 1989, Journal of molecular and cellular cardiology.

[66]  J. K. Gibson,et al.  N-[(omega-amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity. , 1991, Journal of medicinal chemistry.

[67]  D. Roden,et al.  Concentration-dependent pharmacologic properties of sotalol. , 1986, The American journal of cardiology.

[68]  R. Fenici,et al.  Effect of bunaphtine on right atrial repolarisation in man. , 1977, British heart journal.

[69]  H. Refsum,et al.  Class III Antiarrhythmic Action Linked with Positive Inotropy: Antiarrhythmic, Electrophysiological, and Hemodynamic Effects of the Sea‐Anemone Polypeptide ATX II in the Dog Heart in Situ , 1986, Journal of cardiovascular pharmacology.

[70]  N. Taira,et al.  Membrane current changes responsible for the positive inotropic effect of OPC-8212, a new positive inotropic agent, in single ventricular cells of the guinea pig heart. , 1987, The Journal of pharmacology and experimental therapeutics.

[71]  N. El-Sherif,et al.  Effects of clofilium on ischemic subendocardial Purkinje fibers 1 day postinfarction. , 1988, Journal of the American College of Cardiology.

[72]  J. Mason,et al.  Multicenter trial of sotalol for suppression of frequent, complex ventricular arrhythmias: a double-blind, randomized, placebo-controlled evaluation of two doses. , 1986, Journal of the American College of Cardiology.

[73]  A. Jaffe,et al.  Risk factors for sudden death after acute myocardial infarction: two-year follow-up. , 1984, The American journal of cardiology.

[74]  M. I. Steinberg,et al.  Clofilum--a new antifibrillatory agent that selectively increases cellular refractoriness. , 1979, Life sciences.

[75]  F. Rockhold,et al.  Cellular Electrophysiology of Clofilium, a New Antifibrillatory Agent, in Normal and Ischemic Canine Purkinje Fibers , 1981, Journal of cardiovascular pharmacology.

[76]  T. Campbell,et al.  Resting, and rate‐dependent depression of of guinea‐pig ventricular action potentials by amiodarone and desethylamiodarone , 1987, British journal of pharmacology.

[77]  D. A. Lathrop,et al.  Electromechanical characterization of the effects of racemic sotalol and its optical isomers on isolated canine ventricular trabecular muscles and Purkinje strands. , 1985, Canadian journal of physiology and pharmacology.

[78]  W. Rogers,et al.  Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. , 1989, The New England journal of medicine.

[79]  D. Wyse,et al.  Electropharmacology of sotalol in patients with Wolff-Parkinson-White syndrome. , 1987, Circulation.

[80]  H. Nakaya,et al.  Electrophysiological effects of amosulalola new α- and β-adrenoceptor blocker, in isolated rabbit papillary muscles , 1986 .

[81]  R. Shanks,et al.  Indoramin-prolongation of repolarization time, a mechanism of bradycardia in man? , 1985, British journal of clinical pharmacology.

[82]  B. Hoffman,et al.  Effect of procainamide and N-acetylprocainamide on atrial flutter: studies in vivo and in vitro. , 1987, Circulation.

[83]  K. Nademanee,et al.  Pharmacokinetic Significance of Serum Reverse T3 Levels During Amiodarone Treatment: A Potential Method for Monitoring Chronic Drug Therapy , 1982, Circulation.

[84]  J. Klaunig,et al.  Amiodarone and Desethylamiodarone Toxicity in Isolated Hepatocytes in Culture 1 , 1989, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[85]  C. January,et al.  A Model for Early Afterdepolarizations: Induction With the Ca2+ Channel Agonist Bay K 8644 , 1988, Circulation research.

[86]  M. Taams,et al.  Prevention and Treatment of Supraventricular Tachycardia Shortly After Coronary Artery Bypass Grafting: A Randomized Open Trial , 1986, Angiology.

[87]  A. Gomoll,et al.  Comparative beta-blocking activities and electrophysiologic actions of racemic sotalol and its optical isomers in anesthetized dogs. , 1986, European journal of pharmacology.

[88]  A. S. Harris Delayed Development of Ventricular Ectopic Rhythms following Experimental Coronary Occlusion , 1950, Circulation.

[89]  M. Aomine Multiple electrophysiological actions of amiodarone on guinea pig heart , 1988, Naunyn-Schmiedeberg's Archives of Pharmacology.

[90]  B. Lucchesi,et al.  Effects of Pimobendan (UD‐CG 115 BS), a New Positive Inotropic Agent, on Ventricular Tachycardia and Ischemic Ventricular Fibrillation in a Conscious Canine Model of Recent Myocardial Infarction , 1988, Journal of cardiovascular pharmacology.

[91]  B. Singh,et al.  Acute and chronic effects of ketanserin on the electrophysiologic properties of isolated rabbit ventricular myocardium: particular reference to repolarization. , 1988, American heart journal.

[92]  K. Kamiya,et al.  Electrophysiological effects of OPC‐88117, a new antiarrhythmic agent on papillary muscles and single ventricular myocytes isolated from guinea‐pig hearts , 1989, British journal of pharmacology.

[93]  B. Singh,et al.  Historical development of the concept of controlling cardiac arrhythmias by lengthening repolarization: particular reference to sotalol. , 1990, The American journal of cardiology.

[94]  P. Leveque Anti-arrhythmic Action of Bretylium , 1965, Nature.

[95]  J. Weirich,et al.  Electrophysiological profile of KC 8857, a new bradycardic agent , 1987 .

[96]  J. Sundsfjord,et al.  Amiodarone inhibits the conversion of thyroxine to triiodothyronine in isolated rat hepatocytes. , 1984, Endocrinology.

[97]  P. Somani Basic and Clinical Pharmacology of Amiodarone: Relationship of Antiarrhythmic Effects, Dose and Drug Concentrations to Intracellular Inclusion Bodies , 1989, Journal of clinical pharmacology.

[98]  G. Isenberg,et al.  The role of sodium channels in the effects of the cardiotonic compound DPI 201-106 on contractility and membrane potentials in isolated mammalian heart preparations. , 1985, European journal of pharmacology.

[99]  J. Parratt,et al.  Antiarrhythmic actions of meptazinol, a partial agonist at opiate receptors, in acute myocardial ischaemia , 1983, British journal of pharmacology.

[100]  H. Refsum,et al.  Arrhythmogenic, antiarrhythmic and inotropic properties of opioids. Effects of piritramide, pethidine and morphine compared on heart muscle isolated from rats. , 1987, Pharmacology.

[101]  A. Ferroni,et al.  Electrophysiological aspects of the action of bunaphtide on single cardiac muscle fibres , 1973 .

[102]  S. E. Freeman,et al.  Blockade of a cardiac K+ channel by tacrine: interactions with muscarinic and adenosine receptors. , 1988, European journal of pharmacology.

[103]  W. Osterrieder 9‐Amino‐1,2,3,4‐tetrahydroacridine (THA) is a potent blocker of cardiac potassium channels , 1987, British journal of pharmacology.

[104]  Effects of TYB-3823, a new antiarrhythmic drug, on the electrophysiological properties of guinea-pig ventricular muscles. , 1990, General pharmacology.

[105]  R. Gomez,et al.  Synthesis and cardiac electrophysiological activity of aryl-substituted derivatives of the class III antiarrhythmic agent sematilide. Potential class I/III agents. , 1990, Journal of medicinal chemistry.

[106]  H Ichikawa,et al.  Neural networks applied to structure-activity relationships. , 1990, Journal of medicinal chemistry.